CAS: 627-21-4; Pent-2-Yne

上下游产品

CAS号21571-91-5 3,3-dichloropentane | CAS号5398-25-4 Pentane, 2,3-dibromo | CAS号627-19-0 1-戊炔 | CAS号558-37-2 3,3-二甲基-1-丁烯 | CAS号57155-03-0 2-methylbut-1-e... | CAS号115-11-7 2-甲基丙烯 | CAS号64-67-5 硫酸二乙酯 | CAS号463-49-0 丙二烯 | CAS号7611-86-1 cis-1-chloro-1-... | CAS号7611-87-2 1-氯-1-丁烯 | CAS号504-60-9 间戊二烯 | CAS号627-20-3 顺-2-戊烯 | CAS号109-67-1 1-戊烯 | CAS号503-17-3 2-丁炔 | CAS号928-49-4 3-己炔 | CAS号107-87-9 2-戊酮 | CAS号96-22-0 3-戊酮 | CAS号646-04-8 反-2-戊烯 | CAS号109-66-0 正戊烷 | CAS号23454-01-5 2,2-dichlorobutanal

📜2,2-二氯戊烷置于potassium Carbonate体系中,化学反应生成 2-戊炔
参考文献:Faworski,Journal Fur Praktische Chemie (Leipzig 1954),1888,Vol. <2>37,P. 388
标题:Faworski,Journal Fur Praktische Chemie (Leipzig 1954),1888,Vol. <2>37,P. 388

专利信息

专利号:US-7247752-B2
优先权日:2004-10-01
标 题 :Methods for the synthesis of astaxanthin
发明人：LOCKWOOD SAMUEL F; TANG PENG CHO; NADOLSKI GEOFF; JACKSON HENRY L; FANG ZHIQIANG; DU YISHU; YANG MIN; GEISS WILLIAM; WILLIAMS RICHARD; BURDICK DAVID
权利人:CARDAX PHARMACEUTICALS INC
摘要:A method used for synthesizing intermediates for use in the synthesis of carotenoids and carotenoid analogs, and/or carotenoid derivatives. In some embodiments, the invention includes methods for synthesizing optically active intermediates useful for the synthesis of optically active carotenoids. Synthesis of optically active carotenoids, in one embodiment, may be accomplished by forming an optically active dihydroxy intermediate from ketoisopherone. The optically active dihydroxy intermediate may be converted into optically active astaxanthin derivatives.

专利号:US-9126995-B2
优先权日:2011-11-08
标题:Method for catalytic asymmetric synthesis of optically active isoxazoline compound and optically active isoxazoline compound
发明人：TOYAMA KEN-ICHI; MORIYAMA YUJI; MATOBA KAZUTAKA; YAOSAKA MANABU; IKEDA EITATSU
权利人:NISSAN CHEMICAL IND LTD
摘要:There is provided a method for catalytic asymmetric synthesis of optically active isoxazoline compound and an optically active isoxazoline compound. A method for catalytic asymmetric synthesis of optically active isoxazoline compound of a formula (6) including reacting an α,β-unsaturated carbonyl compound of a formula (1) and a hydroxylamine in a solvent in the presence of a base by adding a chiral phase transfer catalyst. An optically active isoxazoline compound of a formula (13) that can be synthesized by the method.

专利号:US-8058414-B2
优先权日:2008-04-29
标题 :Unnatural polymerase substrates that can sustain enzymatic synthesis of double stranded nucleic acids from a nucleic acid template and methods of use
发明人：MENCHEN STEVEN; ROSENBLUM BARNETT; KENNEY PAUL; KHAN SHOEB; MA ZHAOCHUN; CHEN JER-KANG; LAM JOE Y; HUANG BOLI
权利人:MENCHEN STEVEN; ROSENBLUM BARNETT; KENNEY PAUL; KHAN SHOEB; MA ZHAOCHUN; CHEN JER-KANG; LAM JOE Y; HUANG BOLI; LIFE TECHNOLOGIES CORP
摘要:Nucleotide analogs that can sustain the enzymatic synthesis of double-stranded nucleic acid from a nucleic template are described. The nucleotide analogs include: (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine, uracil and their analogs; (ii) a label attached to the base or analog of the base via a cleavable linker; (iii) a deoxyribose; and (iv) one or more phosphate groups. The linker and/or the label inhibits template directed polymerase incorporation of a further nucleotide substrate onto an extended primer strand. In addition, cleavage of the linker leaves a residue attached to the base which is not present in the natural nucleotide and which does not inhibit extension of the primer strand. The nucleotide analogs can therefore be used as reversible terminators in sequencing by synthesis methods without blocking the 3′ hydroxyl group. Methods of sequencing DNA using the substrates are also described.

专利号:US-2003162992-A1
优先权日:2001-12-14
标 题 :Preparation of intermediates useful in the synthesis of antiviral nucleosides
发明人：WATANABE KYOICHI A; DU JINFA
摘要:The present invention is an efficient process for the manufacture of α-acyloxyacetaldehyde, a key intermediate in the synthesis of 1,3-oxathiolane and 1,3-dioxolane nucleosides.

专利号:US-2023286918-A1
优先权日:2020-07-02
标 题:Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat
发明人：JURKAUSKAS VALDAS; JUNG YOUNG CHUN; KWON TAESOO; KANNAN ARUNACHALAM; GONDI VIJAYA BHASKER
权利人:AKEBIA THERAPEUTICS INC
摘要:Disclosed herein are methods and processes of preparing vadadustat or a pharmaceutically acceptable salts thereof, and intermediates (e.g., a compound of Formula (I), (I-F), (II), or (IV), or a pharmaceutically acceptable salts thereof) useful for the synthesis of vadadustat.

专利号:US-2008125587-A1
优先权日:2006-05-25
标 题 :Synthesis of triazole compounds that modulate HSP90 activity
发明人：CHIMMANAMADA DINESH U; LEE CHI-WAN; JAMES DAVID; ZHANG SHIJIE; YING WEIWEN; CHAE JUNGHYUN; PRZEWLOKA TERESA
权利人:CHIMMANAMADA DINESH U; LEE CHI-WAN; JAMES DAVID; ZHANG SHIJIE; YING WEIWEN; CHAE JUNGHYUN; PRZEWLOKA TERESA
摘要:The present invention provides novel methods of preparing triazole compounds which inhibit the activity of Hsp90. One embodiment of the invention is directed to methods for preparing a triazole compound represented by the following Structural Formula: n n n n n n n n n n or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising the steps of: a) reacting an amide represented by the following Structural Formula: n n n n n n n n n n with a thionation reagent to form a thioamide; b) reacting the thioamide of step a) with hydrazine to form a hydrazonamide; c) reacting the hydrazonamide of step b) with a carbonylation or a thiocarbonylation reagent. n In one embodiment, the present invention is a method of synthesis of a compound of formula (IA) n n n n n n n n n n or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising reacting a compound of formula (IIA) n n n n n n n n n n with an oxidizing agent, thereby producing a compound of formula (IA). n The present invention is also directed to a method of preparing a compound or a tautomer thereof represented by the following Structural Formula: n n n n n n n n n n or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof. The method comprises the step of reacting a first starting compound represented by the following Structural Formula: n n n n n n n n n n in the presence of a mercuric salt, with a second starting compound represented by the following Structural Formula: